查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1427234

全球抗凝血劑市場規模、佔有率、成長分析、按藥物類別、分銷管道 - 2023-2030 年產業預測

Global Anticoagulants Market Size, Share, Growth Analysis, By Drug class(Vitamin K Antagonists (VKAs) and Direct Oral Anticoagulants (DOACs)), By Distribution channel(Hospital Pharmacies, Retail Pharmacies) - Industry Forecast 2023-2030
出版日期: | 出版商: SkyQuest | 英文 157 Pages | 商品交期: 3-5個工作天內

價格
簡介目錄

2022年全球抗凝血藥物市場規模為285億美元，預計將從2023年的314.4億美元增至2031年的688.7億美元，並預計在預測期內（2024-2031年）持續成長。）複合年成長率為10.30%。

近年來，隨著慢性病的流行和不健康的生活習慣導致心血管疾病的增加，全球抗凝血藥物市場出現了顯著成長。因此，市場上對抗凝劑的需求不斷增加。根據世界衛生組織 (WHO) 和 Cureus 醫學科學雜誌的數據，心血管疾病位居全球頭號死因之一，每年約造成 1790 萬人死亡，佔全球整體死亡人數的 35%。其中 85% 的死亡是由於心臟病和中風造成的。缺血性心臟疾病(IHD) 已成為全球死亡率的重要原因，影響約 1.26 億人，約佔世界人口的 1.72%。據預測，到 2030 年，IHD 盛行率預計將超過每 10 萬人 1,845 人。抗凝血劑透過防止血液凝固，在降低心臟病、中風和其他心血管併發症的風險方面發揮重要作用。除了傳統的抗凝血治療之外，新型口服抗凝血劑（NOAC）也引起了人們的關注。這些新藥比Warfarin等傳統抗凝血劑具有優勢，包括改進的安全性、更簡單的給藥方案和更少的藥物交互作用。醫療保健專業人員和患者擴大採用 NOAC，進一步推動了全球抗凝血劑市場的成長。

自上而下和自下而上的方法已用於估計和檢驗全球抗凝血劑市場的規模，並估計其他各個相關子市場的規模。用於估計市場規模的調查方法包括以下細節：透過二次研究確定市場中的主要企業，並透過初步和二次研究確定每個地區的市場佔有率。整個過程包括研究主要企業的年度和財務報告以及廣泛的採訪，以獲得執行長、副總裁、董事和行銷負責人等行業領導者的重要見解。所有股份比率和細分均使用二手資訊確定並使用主要資訊檢驗。所有可能影響本研究涵蓋的市場的參數都經過了詳細的考慮和研究，透過初步研究檢驗和分析，以獲得最終的定量和定性資料。

全球抗凝血劑市場細分分析

全球抗凝血劑市場按藥物類別、分銷管道和地區細分。依藥物類別分為維生素K拮抗（vkas）和直介面服抗凝血劑（doacs）。根據分銷管道，市場分為醫院藥房、零售藥房和網路藥房。從區域來看，市場分為北美、歐洲、亞太地區、中東和非洲以及拉丁美洲。

全球抗凝血市場的促進因素

全球抗凝血劑市場的關鍵促進因素之一是全球心血管疾病（包括缺血性心臟疾病（IHD））盛行率的不斷上升。心血管疾病每年導致數百萬人死亡，增加了對預防心臟病和中風的有效治療方法的需求。疾病負擔的增加導致抗凝血劑的需求增加，推動市場成長。此外，與傳統抗凝血劑相比，新型口服抗凝血劑（NOAC）的採用提高了安全性和便利性，進一步刺激了市場擴張。

全球抗凝血藥市場的限制因素

全球抗凝血藥物市場的一個顯著限制是與抗凝血治療相關的出血併發症的可能性。抗凝血劑在預防血栓方面發揮重要作用，但它們也會增加出血事件的風險，在某些情況下可能危及生命。平衡抗凝血治療的益處和潛在副作用對醫療專業人員來說是一個挑戰。此外，與抗凝血劑相關的高成本阻礙了其可用性，特別是在新興市場，進一步限制了市場成長。

全球抗凝血藥物市場趨勢

全球抗凝血藥物市場的一個顯著趨勢是，相對於Warfarin等傳統抗凝血療法，人們越來越青睞直介面服抗凝血藥物（DOAC）。 DOAC 具有劑量可預測、藥物交互作用較少、減少頻繁監測的需要、提高病患依從性等優點。向 DOAC 的轉變是由於其便利性和更高的安全性。此外，正在進行的研究和開發旨在擴大 DOAC 的適應症，使其在市場上越來越受歡迎。

目錄

  • 執行摘要
  • 調查方法
  • 母市場分析
  • 主要市場考察
    • 技術分析
    • 價格分析
    • 供應鏈分析
    • 價值鏈分析
    • 市場生態系統
    • 智慧財產權分析
    • 貿易分析
    • Start-Ups分析
    • 原料分析
    • 創新矩陣
    • 研發線產品分析
    • 總體經濟指標
    • 主要投資分析
    • 關鍵成功因素
    • 競爭程度
  • 市場動態及展望
    • 市場動態
      • 促進因素
      • 機會
      • 抑制因素
      • 任務
    • 監管形勢
    • 波特的分析
    • 對未來中斷的特殊考慮
  • 全球抗凝血劑市場：依藥物類別
    • 市場概況
    • 維生素 K 拮抗劑 (VKA) 和直介面服抗凝血劑 (DOAC)
  • 全球抗凝血劑市場：按分銷管道分類
    • 市場概況
    • 醫院藥房
    • 零售藥房
    • 網路藥房
  • 全球抗凝血劑市場規模：按地區分類
    • 市場概況
    • 北美洲
      • 美國
      • 加拿大
    • 歐洲
      • 德國
      • 西班牙
      • 法國
      • 英國
      • 其他歐洲國家地區
    • 亞太地區
      • 中國
      • 印度
      • 日本
      • 韓國
      • 其他亞太地區
    • 拉丁美洲
      • 巴西
      • 其他拉丁美洲地區
    • 中東和非洲 (MEA)
      • 海灣合作理事會國家
      • 南非
      • 其他中東/非洲地區
  • 競爭形勢
    • 前5名企業對比
    • 主要企業市場定位（2021年）
    • 主要市場參與者所採取的策略
    • 關鍵成功策略
    • 近期市集活動
    • 主要企業市場佔有率（2021年）
  • 主要企業簡介
    • Pfizer Inc.（US）
    • Bayer AG（Germany）
    • Bristol Myers Squibb Company（US）
    • Johnson & Johnson（US）
    • Boehringer Ingelheim International GmbH（Germany）
    • Sanofi SA（France）
    • Daiichi Sankyo Company, Limited（Japan）
    • Novartis International AG（Switzerland）
    • Eli Lilly and Company（US）
    • AstraZeneca PLC（UK）
    • Merck & Co., Inc.（US）
    • GlaxoSmithKline PLC（UK）
    • Abbott Laboratories（US）
    • Aspen Pharmacare Holdings Limited（South Africa）
    • Otsuka Holdings Co., Ltd.（Japan）
    • Mylan NV（US）
    • Takeda Pharmaceutical Company Limited（Japan）
    • Leo Pharma A/S（Denmark）
    • Portola Pharmaceuticals, Inc.（US）
    • CSL Limited（Australia）
簡介目錄
Product Code: SQMIG35B2093

Global Anticoagulants Market size was valued at USD 28.50 Billion in 2022 and is expected to grow from USD 31.44 Billion in 2023 to reach USD 68.87 Billion by 2031, at a CAGR of 10.30% during the forecast period (2024-2031).

The global anticoagulants market has experienced substantial growth recently, propelled by the increasing prevalence of chronic diseases and the adoption of unhealthy lifestyles contributing to a rise in cardiovascular diseases. This has led to a heightened demand for anticoagulants in the market. According to the World Health Organization (WHO) and the Cureus Journal of Medical Science, cardiovascular diseases rank among the leading causes of global mortality, accounting for around 17.9 million deaths annually, representing 35% of total global deaths. Within these fatalities, 85% are linked to heart attacks and strokes. Ischemic heart disease (IHD) has emerged as a significant contributor to worldwide mortality, affecting approximately 126 million individuals globally, representing about 1.72% of the global population. Projections suggest that the prevalence of IHD is anticipated to exceed 1,845 per 100,000 individuals by the year 2030. Anticoagulants play a crucial role in preventing blood clotting, thereby reducing the risk of heart attacks, strokes, and other cardiovascular complications. Alongside traditional anticoagulant therapies, novel oral anticoagulants (NOACs) have gained prominence. These newer drugs offer advantages such as improved safety profiles, simplified dosing regimens, and fewer drug interactions compared to traditional anticoagulants like warfarin. The increasing adoption of NOACs by healthcare professionals and patients has further propelled the growth of the global anticoagulants market.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Anticoagulants Market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Anticoagulants Market Segmental Analysis

Global Anticoagulants Market is segmented by drug class, distribution channel, and region. Based on drug class, the market can be segmented into vitamin k antagonists (vkas), and direct oral anticoagulants (doacs). Based on distribution channel, the market is segmented into hospital pharmacies, retail pharmacies, and online pharmacies. Based on region, the market is segmented into North America, Europe, Asia Pacific, Middle East and Africa, and Latin America.

Drivers of the Global Anticoagulants Market

One key driver of the global anticoagulants market is the increasing prevalence of cardiovascular diseases, including ischemic heart disease (IHD), worldwide. With millions of deaths each year attributed to cardiovascular diseases, there is a growing need for effective treatments to prevent heart attacks and strokes. This rising disease burden has resulted in a higher demand for anticoagulant medications, driving the growth of the market. Additionally, the adoption of novel oral anticoagulants (NOACs) has further fueled the market expansion, offering improved safety and convenience compared to traditional anticoagulants.

Restraints in the Global Anticoagulants Market

A notable constraint for the global anticoagulants market is the potential for bleeding complications linked to anticoagulant therapy. Although these medications play a crucial role in preventing blood clots, they also elevate the risk of bleeding events, which, in certain instances, can be life-threatening. Balancing the benefits of anticoagulant therapy against the potential adverse effects poses a challenge for healthcare professionals. Moreover, the high cost associated with anticoagulant medications can impede their accessibility, particularly in developing regions, further constraining the growth of the market.

Market Trends of the Global Anticoagulants Market

A notable trend in the global anticoagulants market is the growing preference for direct oral anticoagulants (DOACs) over traditional anticoagulant therapies like warfarin. DOACs present benefits such as predictable dosing, fewer drug interactions, and reduced necessity for frequent monitoring, enhancing patient adherence. The shift towards DOACs is propelled by their convenience and improved safety profiles. Furthermore, ongoing research and development endeavors aim to broaden the scope of indications for DOACs, contributing to their increasing popularity in the market.

Table of Contents

  • Executive Summary
    • Market Overview
    • Wheel of Fortune
  • Research Methodology
    • Information Procurement
    • Secondary & Primary Data Sources
    • Market Size Estimation
    • Market Assumptions & Limitations
  • Parent Market Analysis
    • Market Overview
    • Market Size
    • Market Dynamics
      • Drivers
      • Opportunities
      • Restraints
      • Challenges
  • Key Market Insights
    • Technology Analysis
    • Pricing Analysis
    • Supply Chain Analysis
    • Value Chain Analysis
    • Ecosystem of the Market
    • IP Analysis
    • Trade Analysis
    • Startup Analysis
    • Raw Material Analysis
    • Innovation Matrix
    • Pipeline Product Analysis
    • Macroeconomic Indicators
    • Top Investment Analysis
    • Key Success Factor
    • Degree of Competition
  • Market Dynamics & Outlook
    • Market Dynamics
      • Drivers
      • Opportunities
      • Restraints
      • Challenges
    • Regulatory Landscape
    • Porters Analysis
      • Competitive rivalry
      • Threat of Substitute Products
      • Bargaining Power of Buyers
      • Threat of New Entrants
      • Bargaining Power of Suppliers
    • Skyquest Special Insights on Future Disruptions
      • Political Impact
      • Economic Impact
      • Social Impact
      • Technical Impact
      • Environmental Impact
      • Legal Impact
  • Global Anticoagulants Market by Drug class
    • Market Overview
    • Vitamin K Antagonists (VKAs) and Direct Oral Anticoagulants (DOACs)
  • Global Anticoagulants Market by Distribution channel
    • Market Overview
    • Hospital Pharmacies
    • Retail Pharmacies
    • and Online Pharmacies
  • Global Anticoagulants Market Size by Region
    • Market Overview
    • North America
      • USA
      • Canada
    • Europe
      • Germany
      • Spain
      • France
      • UK
      • Rest of Europe
    • Asia Pacific
      • China
      • India
      • Japan
      • South Korea
      • Rest of Asia-Pacific
    • Latin America
      • Brazil
      • Rest of Latin America
    • Middle East & Africa (MEA)
      • GCC Countries
      • South Africa
      • Rest of MEA
  • Competitive Landscape
    • Top 5 Player Comparison
    • Market Positioning of Key Players, 2021
    • Strategies Adopted by Key Market Players
    • Top Winning Strategies
      • By Development
      • By Company
      • By Year
    • Recent Activities in the Market
    • Key Companies Market Share (%), 2021
  • Key Company Profiles
    • Pfizer Inc. (US)
      • Company Overview
      • Business Segment Overview
      • Financial Updates
      • Key Developments
    • Bayer AG (Germany)
      • Company Overview
      • Business Segment Overview
      • Financial Updates
      • Key Developments
    • Bristol Myers Squibb Company (US)
      • Company Overview
      • Business Segment Overview
      • Financial Updates
      • Key Developments
    • Johnson & Johnson (US)
      • Company Overview
      • Business Segment Overview
      • Financial Updates
      • Key Developments
    • Boehringer Ingelheim International GmbH (Germany)
      • Company Overview
      • Business Segment Overview
      • Financial Updates
      • Key Developments
    • Sanofi S.A. (France)
      • Company Overview
      • Business Segment Overview
      • Financial Updates
      • Key Developments
    • Daiichi Sankyo Company, Limited (Japan)
      • Company Overview
      • Business Segment Overview
      • Financial Updates
      • Key Developments
    • Novartis International AG (Switzerland)
      • Company Overview
      • Business Segment Overview
      • Financial Updates
      • Key Developments
    • Eli Lilly and Company (US)
      • Company Overview
      • Business Segment Overview
      • Financial Updates
      • Key Developments
    • AstraZeneca PLC (UK)
      • Company Overview
      • Business Segment Overview
      • Financial Updates
      • Key Developments
    • Merck & Co., Inc. (US)
      • Company Overview
      • Business Segment Overview
      • Financial Updates
      • Key Developments
    • GlaxoSmithKline PLC (UK)
      • Company Overview
      • Business Segment Overview
      • Financial Updates
      • Key Developments
    • Abbott Laboratories (US)
      • Company Overview
      • Business Segment Overview
      • Financial Updates
      • Key Developments
    • Aspen Pharmacare Holdings Limited (South Africa)
      • Company Overview
      • Business Segment Overview
      • Financial Updates
      • Key Developments
    • Otsuka Holdings Co., Ltd. (Japan)
      • Company Overview
      • Business Segment Overview
      • Financial Updates
      • Key Developments
    • Mylan N.V. (US)
      • Company Overview
      • Business Segment Overview
      • Financial Updates
      • Key Developments
    • Takeda Pharmaceutical Company Limited (Japan)
      • Company Overview
      • Business Segment Overview
      • Financial Updates
      • Key Developments
    • Leo Pharma A/S (Denmark)
      • Company Overview
      • Business Segment Overview
      • Financial Updates
      • Key Developments
    • Portola Pharmaceuticals, Inc. (US)
      • Company Overview
      • Business Segment Overview
      • Financial Updates
      • Key Developments
    • CSL Limited (Australia)
      • Company Overview
      • Business Segment Overview
      • Financial Updates
      • Key Developments